19 recruiting, 13 completed, 10 not yet recruiting, 4 unknown. 12 Phase 3, 7 Not applicable, 6 Phase 4, 3 Phase 2, 2 Phase 1.
Follow Venous Thromboembolism (VTE): new trials by email Literature Review of Venous Thromboembolism (VTE) trials Research Report on Venous Thromboembolism (VTE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| Vortosiran for VTE Prevention Vortosiran, Placebo - Venous Thromboembolism (VTE), Cancer | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 150 | 2026-10-01 | 2026-09-30 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) REGN7508, REGN9933, Placebo - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1908 | 2026-09-07 | 2026-09-29 |
| Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism DECIDE-VTE Patient Decision Aid - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Not applicable | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 850 | 2026-09-01 | 2026-06-24 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-10-21 |
| Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease Apixaban - Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) | Phase 4 | Not yet recruiting | James Bayley | 50 | 2026-08-01 | 2026-07-20 |
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection YKYY033 Injection, YKYY033 Placebo - Venous Thromboembolism (VTE) | Phase 1 | Recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 40 | 2026-07-10 | 2026-08-26 |
| Delivery and Implementation of a Randomised Crossover Trial on Thrombosis Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery., Low molecular weight heparin (LMWH) - Hip Fractures, Venous Thromboembolism (VTE) | Not applicable | Recruiting | Queen Mary University of London | 21194 | 2026-07-01 | 2026-09-23 |
| Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance Routine clinical care (no study intervention) - Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension | Recruiting | Azienda Ospedaliero-Universitaria Careggi | 5000 | 2026-06-19 | 2026-10-15 | |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| 3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism Pulmonary Embolism (Diagnosis), Venous Thromboembolism (VTE) | Not yet recruiting | Beijing Tsinghua Chang Gung Hospital | 115 | 2026-05-01 | 2026-05-01 | |
| Precision Antithrombotic Therapy Not applicable- observational study - Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE) | Enrolling by invitation | The Third Xiangya Hospital of Central South University | 5000 | 2026-05-01 | 2026-06-17 | |
| Duke Virtual IntEgrated Workflow Co-Care - Falls Injury, Readmission Rates | Not yet recruiting | Duke University | 10000 | 2026-02-04 | 2026-02-12 | |
| A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism CITY-FXI, Placebo - Factor V Leiden, Prothrombin G20210A | Phase 1 | Recruiting | City Therapeutics | 182 | 2026-01-22 | 2026-09-25 |
| Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism Exercise-based rehabilitation program - Venous Thromboembolism (VTE), Exercise Therapy | Not applicable | Recruiting | Insel Gruppe AG, University Hospital Bern | 160 | 2025-12-17 | 2026-06-12 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients Venous Thromboembolism (VTE), Occult Cancer | Recruiting | Infanta Leonor University Hospital | 500 | 2025-12-01 | 2025-12-30 | |
| Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis Low-dose low-molecular-weight heparin - Venous Thromboembolism (VTE), Postpartum | Phase 3 | Recruiting | Marc Blondon | 9200 | 2025-10-15 | 2026-10-06 |
| Informative Video Before LMWH Postpartum - Randomized Controlled Trial Informative Video on LMWH, Standard Verbal Explanation - Venous Thromboembolism (VTE), Postpartum Care | Not applicable | Not yet recruiting | Wolfson Medical Center | 160 | 2025-10-15 | 2025-09-11 |
| TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization Low-Molecular-Weight Heparin (LMWH), Direct Oral Anticoagulants (DOACs), No Thromboprophylaxis Cohort - Lower Extremity Injuries, Venous Thromboembolism (VTE) | Recruiting | University of Monastir | 1500 | 2025-09-01 | 2026-10-07 |
Showing 20 of 47. Sign in to see all of them.
Venous Thromboembolism (47) · Pulmonary Embolism (11) · Venous Thrombosis (10) · Disease (4) · Neoplasms (3) · Anxiety Disorders (2) · Thrombosis (2) · Atrial Fibrillation (1) · Bone Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Critical Illness (1) · Depression (1) · Dyspnea (1) · Emergencies (1) · Heart Arrest (1)
Cardiovascular Diseases (47) · Embolism and Thrombosis (47) · Vascular Diseases (47) · Thromboembolism (46) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Pathological Conditions, Signs and Symptoms (12) · Embolism (11) · Pathologic Processes (10) · Thrombosis (10) · Neoplasms (4) · Disease Attributes (3) · Heart Diseases (3) · Neoplasms by Site (3) · Nervous System Diseases (3)
apixaban (8) · Enoxaparin (7) · Heparin, Low-Molecular-Weight (5) · Aspirin (4) · Rivaroxaban (4) · Dalteparin (2) · Fondaparinux (2) · N(4)-oleylcytosine arabinoside (2) · Tablets (2) · Warfarin (2) · edoxaban (2) · (+-)-(1'R*,2'S*,6'R*)-(2-hydroxy-4,6-dimethoxyphenyl)(3'-methyl-2'-(3''-methylbut-2''-enyl)-6-phenylcyclohex-3'-enyl)methanone (1) · Colchicine (1) · Dabigatran (1) · Electric Stimulation (1)
Regeneron Pharmaceuticals (3) · Assistance Publique Hopitaux De Marseille (2) · Bristol-Myers Squibb (2) · Daiichi Sankyo (2) · University Hospital, Brest (2) · Abu Dhabi Health Services Company (1) · Alexandre Tran (1) · Avexima Diol LLC (1) · Azienda Ospedaliero-Universitaria Careggi (1) · Azienda Sanitaria Locale ASL 6, Livorno (1) · Bayer (1) · Beijing Tsinghua Chang Gung Hospital (1) · Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (1) · Chen Lijuan (1) · China-Japan Friendship Hospital (1)
United States (10) · France (8) · China (6) · Bulgaria (5) · Canada (5) · Germany (5) · Italy (5) · Romania (5) · Hungary (4) · Poland (4) · Spain (4) · Brazil (3) · Denmark (3) · Israel (3) · Netherlands (3)
Alexandre Tran, MD, MSc, FRCSC (1) · Amihai Rottenstreich, MD (1) · Anabel Franco-Moreno, MD, PhD (1) · Anders Gabrielsen, MD, PhD (1) · Anthony Sochet, MD, MSc (1) · Aurelien Delluc, MD, PhD (1) · Ayyaz Ahmad, MBBS, FCPS (1) · Dachun Xu, Ph.D (1) · Eduardo Ramacciotti, MD, Ph.D. (1) · Federico Germini, Doctor of Medicine (1)
PMID 24251360, PMID 24576517, PMID 25040558, PMID 26133379, PMID 26271200, PMID 27232649, PMID 27881569, PMID 28063245, PMID 28617144, PMID 28625365, PMID 28698258, PMID 28762617, PMID 28840662, PMID 28905172, PMID 29188425, PMID 29212126, PMID 29231094, PMID 30252149, PMID 30419597, PMID 30778649, PMID 31215264, PMID 31249989, PMID 32217063, PMID 32538234, PMID 32657973, PMID 33073581, PMID 33709339, PMID 34078109, PMID 36566304, PMID 37855029, PMID 39077587, PMID 41223938
2025 (3), 2009 (1), 2014 (1), 2016 (1)